Myocardial infarction smoking cessation

The FDA has approved the use of 325 mg/d for primary prophylaxis of myocardial infarction but urges caution in this use of aspirin by the general population except when prescribed as an adjunct to risk factor management by smoking cessation and lowering of blood cholesterol and blood pressure. Meta-analysis of many published trials of aspirin and other antiplatelet agents confirms the value of this intervention in the secondary prevention of vascular events among patients with a history of vascular events. 

Jonasou T, Bergstrom R. Cessation of smoking in patients with intermittent claudicatio. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Medical Scandinavica 1987 221 253-260. 

---